524516 BACPHAR

Bacil Pharma Share Price

₹57.72 -1.17 (-1.99%)

27 Dec, 2024 00:59

SIP TrendupStart SIP in BACPHAR

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month + 30.29%
  • Over 3 Month + 112.28%
  • Over 6 Month + 145.62%
  • Over 1 Year + 964.94%
SIP Lightning

Smart Investing Starts Here Start SIP with Bacil Pharma for Steady Growth!

Invest Now

Bacil Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Bacil Pharma Financials

Bacil Pharma Technicals

EMA & SMA

Current Price
₹57.72
-1.17 (-1.99%)
pointer
  • stock-down_img
  • Bullish Moving Average 11
  • stock-up_img
  • Bearish Moving Average 5
  • 20 Day
  • ₹56.48
  • 50 Day
  • ₹48.80
  • 100 Day
  • ₹40.09
  • 200 Day
  • ₹30.68

Resistance and Support

57.72 Pivot Speed
  • R3 57.72
  • R2 57.72
  • R1 57.72
  • S1 57.72
  • S2 57.72
  • S3 57.72

What's your outlook on Bacil Pharma?

You can only vote for once

Bacil Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-23 Quarterly Results
2024-10-15 Others
2024-09-27 Increase in Authorised Capital
2024-08-14 Quarterly Results
2024-05-21 Audited Results

Bacil Pharma F&O

Bacil Pharma Shareholding Pattern

No data available.

About Bacil Pharma

  • NSE Symbol
  • BACPHAR
  • BSE Symbol
  • 524516
  • ISIN
  • INE711D01018

Similar Stocks to Bacil Pharma

Bacil Pharma FAQs

Bacil Pharma share price is ₹57 As on 27 December, 2024 | 00:45

The Market Cap of Bacil Pharma is ₹34 Cr As on 27 December, 2024 | 00:45

The P/E ratio of Bacil Pharma is 88.3 As on 27 December, 2024 | 00:45

The PB ratio of Bacil Pharma is 31.1 As on 27 December, 2024 | 00:45

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23